GBS Vaccine Receives FDA Breakthrough Therapy Designation
ADC评论
September 9, 2022
On September 7, Pfizer announced that its GBS vaccine candidate GBS6 (PF-06760805) has been granted breakthrough therapy designation by the FDA for the prevention of
